Business Wire

Nippon Gases Deploys Juniper Networks’ AI-Native Networking Platform to Foster Growth and Accelerate Innovation

12.12.2024 09:00:00 CET | Business Wire | Press release

Share

New wired and wireless network consolidates and transforms operations to underpin mission-critical gas production across Europe

Juniper Networks®, (NYSE: JNPR), a leader in secure, AI-Native Networking, today announced that Nippon Gases, one of the largest industrial gas companies in Europe, has implemented Juniper’s AI-Native wired and wireless LAN solutions to enhance mobile experiences across Nippon Gases’s IT and operational technology (OT) environments whilst streamlining network operations to foster digital innovation. As a key element of Juniper’s AI-Native Networking Platform, the new infrastructure uses Mist AI and cloud native capabilities to provide industry-leading efficiency, resiliency and visibility to Nippon Gases, resulting in exceptional user and operator experiences across offices, specialty labs, manufacturing plants, trucks, pipelines and ships.

With operations in 13 countries, Nippon Gases produces essential gases such as oxygen, nitrogen, hydrogen and carbon dioxide, serving multiple industries including healthcare, food and beverage, manufacturing and biotech.

By standardizing on Juniper’s unique AI for networking capabilities, Nippon Gases accelerates service deployment, simplifies operations, reduces total cost of ownership (TCO) and operational expenses, delivering exceptional end-to-end user and IT experiences. Additionally, Juniper’s AI-Native Networking Platform will help Nippon Gases accelerate new site set ups, increase trouble-ticket resolution with automation, optimize component inventory management and enable efficient, consistent network operations. The IT team can now automate the base configurations for each site and deploy the network rapidly with Zero Touch Provisioning. Role-based access delegates tasks to local teams while maintaining central control, simplifying maintenance through a standardized network. The IT team can put users’ digital experiences first and reduce the IT workload across the entire network life cycle.

News Highlights:

  • Juniper Mist Wireless (Wi-Fi) Assurance provides the fastest way to deploy and the easiest way to manage personalized Wi-Fi experiences, including up to 90 percent elimination in wireless trouble tickets, up to 85 percent fewer truck rolls and up to 9x faster deployment times in some instances. With Juniper, Nippon Gases’ Wi-Fi is fast, secure and reliable, even in the busiest, most experience-critical areas. For instance: reliable Wi-Fi supports seamless communication between industrial IoT devices, sensors and control systems, ensuring uninterrupted operations and real-time monitoring and enables technicians to access and update digital workflows or maintenance logs instantly.
  • Juniper Mist Wired Assurance delivers reliable, secure connectivity experiences for stationary devices and IoT endpoints through AI-driven network operations.
  • Juniper Networks® EX Series Switches enable unified visibility and control over both wireless and wired networking through a common Mist AI engine and microservices cloud infrastructure.
  • Juniper’s Marvis™ Virtual Network Assistant is used across Nippon Gases’ wired and wireless domains to simplify and automate network operations. Acting as an extended member of the IT team, Marvis provides proactive actions and Self-Driving Network™ operations. It continuously optimizes the user experience and provides visibility into impending problems. As a result, IT operations have clear and secure visibility into user and application experiences. AIOps boosts network reliability with automated actions, optimizing the network in real time and enabling rapid troubleshooting when needed.
  • A Juniper Enterprise Agreement (EA) gives Nippon Gases an easier way to purchase, consume and manage the portfolio of Juniper AI-Native Networking Platform software and support services anywhere in its business.

Supporting Quotes:

“Our business is incredibly dynamic and highly competitive. We are frequently building new factories, expanding our footprint and driving growth through acquisitions. These fast-paced changes mean IT typically has little lead time to support the new business demands that keep us ahead of the market. With Juniper’s AI-Native Networking Platform, we can rapidly yet easily deploy networks at new sites, ensuring seamless, secure connectivity and operational readiness. Juniper’s innovative solutions allow us to scale efficiently and consistently, meet business needs on tight timelines, and maintain the high standards our customers expect of a market leader.”

- Bjorn Dupont, IT Network Manager, Nippon Gases

“Nippon Gases needed to harmonize its complex network infrastructure to improve stability and support quality control. Centralized management was a particular challenge, as IT teams had to manage network devices individually across multiple countries. Simplifying network provisioning and operations therefore became a top priority. This requirement plays to our AI-Native Networking Platform’s strengths—offering insight-driven and automated solutions to mitigate manual, decentralized management. With Juniper, Nippon Gases can quickly identify, monitor and correlate network events in real time, proactively addressing potential issues before they impact operations and experiences.”

- Gos Hein van de Wouw, Vice President, Enterprise Sales, EMEA, Juniper Networks

About Juniper Networks

Juniper Networks believes that connectivity is not the same as experiencing a great connection. Juniper's AI-Native Networking Platform is built from the ground up to leverage AI to deliver the best and most secure user experiences from the edge to the data center and cloud. Additional information can be found at Juniper Networks (www.juniper.net) or connect with Juniper on X (Twitter), LinkedIn, and Facebook.

Juniper Networks, the Juniper Networks logo, Juniper, Junos, and other trademarks listed here are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241212532821/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye